Theporosity of the granules of formulation 1 is higher which results in fasterdissolution of the API. The produced tablets under same tablettingconditions from both formulations have similar hardness and thicknessvalues. The disintegration is slower for formulation 1 while the dissolu-tion is faster and is also shown to be pH influenced (Fig. 2, 3).This suggests that indeed changing the granulator could result in adifference in a product's final characteristics.Fig. 1. Particle size distribution of granulatesFig. 2. Dissolution rate of API in pH=1.2Fig. 3. Dissolution rate of API in pH=4.5references[1] DM Parikh, Handbook of Pharmaceutical Granulation Technology, Marcel DekkerINC, New York, 1997,: 205-212. [2] DS Hausman, Comparison of low shear, high shear, and fluid bed granulation dur-ing low dose tablet process development. Drug Dev Ind Pharm. 2004: 30, (3): 259-66. [3] D Oulahna, F Cordier, L Galet, JA Dodds, Wet granulation: the effect of shear ongranule properties, Powder Technology, 2003: 130, (1-3): 238-246. [4] http://www.druginfosys.com/SPOREDbA NA KARAKTERISTIKINA GRANUlI I TAblETI PROIzVEDENISO low shear I high shearGRANUlATORSunchitsa Jordanoska, Krume Toshev,Natasha A.Stojanovska, Ivana Mitskoska,Tina Mitrulovska, Sonja UgarkovikjIstrazhuvanje i razvoj, ALKALOID AD, Aleksandar Makedonski 12,1000 Skopje, Republika MakedonijaVOVED I TsElVlazhna granulatsija e se ushte mnogu chesta postapka pri formuli-ranje na tableti. Za lekovi koi nemaat kompresibilni karakteri-stiki ovoj metod se pretpochita pred direktnata kompresija. Denesvo vlazhnata granulatsija najchesto se koristi high shear mikser. Po-stojat i povekje konventsionalni alternativi koi generiraat poma-la brzina a isto taka se ushte se koristat. Iskustvoto pokazhuvadeka karakteristikite na proizvodot mozhe da bidat pod silno vli-janie na vidot na opremata koja se koristi za granulatsija. Nekoiparametri za koi e zabelezhano deka se najmnogu afektirani senasipna gustina, poroznost i distributsija po golemina na granuli.Nashata tsel beshe da se sporedat efektite od razlichnite vidovina oprema za granulatsija (high shear v.s. low shear granulator) nakontrolnite parametri na granuli i tableti.METODOlOGIJAOvaa studija beshe izvedena vo Istrazhuvanje i Razvoj, Alkaloid AD- Skopje. Za nashite tseli bea napraveni dve formulatsii na tabletiso ist sostav (Tabela 1), so visoka sodrzhina na API od ssa 60% protableta. Koristenata API ima pKa vrednost od 2,5 i pripagja na BCSklasa IV. Formulatsija 1 beshe granulirana vo low shear granulator- laboratoriska oprema za mesenje (model: Erweka LK5), a zagranulatsija na formulatsijata 2 beshe koristen high shear miksergranulator (model: Diosna P 06/01) (Tabela 2). Dobienite vlazhnigranulati bea pominati niz ostsilirachko rende (1,5 mm). Potoa gra-nulat 1 e sushen vo laboratoriska sushnitsa. Za sporedba, granulat2 e sushen vo fluid-bed sushach. Dvata granulati bea susheni do po-stignuvanje na sodrzhina na vlaga pomalku od 10%. Po zavrshuvanjetona protsesot na sushenje suvite granulati povtorno bea pominatiniz ostsilirachko rende (0,8 mm).Tabela 1. Komponenti na formulatsii 1 i 2236PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAoralni prezentatsiiTabela 2. Protsesni chekori i vid na opremata shto se koristi zaformulatsiite 1 i 2REzUlTATI, DISKUSIJA I zAKlUChOKOd sekoja formulatsija beshe zemen reprezentativen primerok odgranulite i tabletite i ispitan za kontrolnite parametri: nasipnai natapkana gustina, protochni karakteristiki, poroznost, distri-butsija po golemina na granuli, tsvrstina, visina i dezintegratsija.Isto taka beshe izveden i disolutsiski test vo dva mediumi sorazlichna pH vrednost. Rezultatite se prikazhani vo Tabela 3:Tabela 3. Kluchni kontrolni parametri za granulati i tabletiRezultatite pokazhuvaat deka granulite proizvedeni vo low sheargranulator (formulatsija 1) se so poniska nasipna i natapkanagustina. Protochnite karakteristiki se slichni, a Hausner-oviotodnos i Carr-oviot indeks ostanuvat isti za dvete formulatsii, shtopokazhuva deka kompresibilnite karakteristiki ne se afektirani.Granulite na formulatsijata 1 se isto taka pogolemi od onie naformulatsijata 2 shto e prikazhano preku sporedba na krivite nadistributsija po golemina na Cl. 1. Poroznosta na granulite odformulatsijata 1 e povisoka, shto rezultira so pobrza disolutsijana API. Proizvedenite tableti od dvete formulatsii, pod istiuslovi na tabletiranje, imaat slichni vrednosti za tsvrstinite ivisinite. Dezintegratsijata e pobavna za formulatsijata 1, adisolutsijata pobrza i pH-zavisna (Cl. 2, 3). Ova ukazhuva na toa dekanavistina promena na granulatorot mozhe da rezultira so razlikivo karakteristikite na konechniot proizvod.Sl. 1. Distributsija po golemina na granuliSl. 2. Brzina na disolutsija na API vo rN = 1,2Sl. 3 Brzina na disolutsija na API API vo rN = 4,5lITERATURA[1] DM Parikh, Handbook of Pharmaceutical Granulation Technology, Marcel DekkerINC, New York, 1997,: 205-212[2] DS Hausman, Comparison of low shear, high shear, and fluid bed granulation dur-ing low dose tablet process development. Drug Dev Ind Pharm. 2004: 30, (3): 259-66. [3] D Oulahna, F Cordier, L Galet, JA Dodds, Wet granulation: the effect of shear ongranule properties, Powder Technology, 2003: 130, (1-3): 238-246. [4] http://www.druginfosys.com/237fifth congress of PharMacy of Macedonia with international ParticiPationMacedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYoral presentationsPhysico-cheMical ProPertiesof Plga aMPhiPilic nanoParticlesand solid tuMor targetingM. Simonoska Crcarevska1, N. Geskovski1, M. GlavasDodov1, S. Calis2, S. Dimcevska1, K. Goracinova11Faculty of Pharmacy, University of Ss Cyril and Methodius,Vodnjanska 17, 1000 Skopje, Macedonia2Faculty of Pharmacy, Haccetepe University, 06100Ankara, TurkeyPolymer therapeutics for cancer therapy is a promising field for de-velopment of alternative strategies to standardized chemotherapytreatment regime. Formulation relied on drug delivery technologiesproficiently modify and control drug release profile, absorption,distribution and elimination for the benefit of improving productefficacy and safety, as well as patient convenience and compliance.Development of drug delivery systems (DDS) that would target thedrug specifically and exclusively to tumor tissue, and at the same timewould provide adequate drug release profile is major challenge in ra-tionale design of innovative DDS for solid tumor targeting. Having inmind that passive targeting (Fig 1), utilizing the unique abnormalitiesassociated with tumor tissue, is mostly used approach, special atten-tion should be paid on the physico-chemical properties of the de-signed DDS. Size and surface of the nanoparticulate carrier play avery crucial role with respect to uptake by the tumour.The present work is related to design and development of a modelnanoparticulated DDS with tumour targeting ability. FDA approvedsynthetic polymers, Poly(D,L-lactide-co-glycolide) (85:15) (PLGA) andpolyethylene oxide (PEO) tri-block copolymer Pluronic F127 were usedfor formulation of the nanoparticles (NP). Irinotecan hydrochlorid (IR-HCl), water soluble substance was used as model drug substance.Fig. 1. Passive accumulation of drug-loaded nanoparticles in tumortissues via the EPR effectHaving in mind that formulation of polymeric nanoparticles (NP) ascarriers for hydrophilic drugs is problematic, since the drug is expelledfrom the hydrophobic matrix into the dispersing water phase duringNP preparation, we faced our experiments towards modification ofstandard nanoprecipitation method (Fig. 2) [1, 2]Fig 2. Schematic presentation of modified nanoprecipitation prepa-ration procedureKnowing the fact that mixing of two liquids mainly depends from dif-ferences in surface tension that have impact on mass exchange ratioand consequently would influence encapsulation efficiency (EE), thecrucial step in modifying the nanoprecipitation procedure was selec-tion of appropriate solvent for IR-HCl (ethanol acetonitrile, PEG-200,water). Implying that solubility of IR-HCl in all selected solvents wassimilar, obtained differences in EE are allegedly related to differencesin surface tensions between drug solvent and polymer solvent. Whenwater as drug solvent was used the highest EE (~50%) was obtained.Prospects for unique interaction of prepared NP with biological sys-tems at molecular level are immense, since particle size of preparedNP (~ 120 nm) was in a required range of 20-200 nm. In fact, NP arelarge to avoid premature elimination via glomerular filtration in thekidneys, but are small enough to enter blood vessels and to capitalizeon EPR effect for passive accumulation in the target tumor tissues [3].Having in mind that low charged particles have a much loweropsonization rate than charged particles, measured zeta potential ofNP (-1 to -5 mV) was in favor of prolonged blood circulation time andhence, EPR effect, thus postponing the time when NP would be rec-ognized by reticuloendothelial system (RES) and hence, removed fromthe body. Also, to circumvent the problem associated with opsoniza-tion, the surface of nanoparticles must be sterically stabilized. Thiscould be achieved by adsorption of Pluronic F127 onto the surface ofNP. Presence of PEO chains on the surface of NP should reduce theamount of unspecific protein adsorption (opsonization) and is ex-pected to drastically increase the blood circulation time and there-fore to influence biodistribution of the particles. Using standarddepletion method [4] amount of F127 incorporated and tightly boundto PLGA, was determined. Results indicated its dependency from theinitial F127 quantity (0,28-0,83%) used during preparation procedure.Schematic presentation of odds on surface exterior of prepared NP ispresented on Fig 3.a) b) c)Fig.3. Schematic presentation of NP prepared with different quantityof F127 a) 0,28% F127; b) 0,55% F127 and c) 0,83% F127By conducting adsorption studies with BSA [5], the influence of in-corporated F127 into the NP on protein adsorption was determined,238PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAoralni prezentatsiiand hence, possibility for opsonization was predicted. Future experi-ments will be directed to assessment and correlation of these resultsto the results from performed in vivo studies on healthy as well astumor model animals. In fact by in vivo studies the influence ofphysico-chemical properties of prepared NP to solid tumor targetingperformance would be evaluated.references[1] Glavas, M., Calis, S., Simonoska M., Geskovski, N., Goracinova, K. (2011). Colloidalcarriers for anticancer drug delivery - formulation aspects, Proceedings ofInternational Symposium on Drug Research and Development, Antalya, Turkey[2] Simonoska Crcarevska, M., Geskovski, N., Kuzmanovska, S., Glavas Dodov, M.,Calis, S., Goracinova, K. (2011). Preparation and biological evaluation of irinotecanloaded biodegradable nanocarriers for tumour delivery by EPR effect, Proceedingsof 3rd PharmSciFair, Prague, Czech Republic[3] Ebrahim Attia, A. B., Ong, Z. Y., Hedrick, J. L., Lee, P. P., Ee, P. L. R., Hammond, P.T., Yang, Y.Y. (2011). Mixed micelles self-assembled from block copolymers for drugdelivery. Curr Opin Colloid In, 16: 182-194. [4] Shar, J. A., Obey, T. M., Cosgrove, T. (1998). Adsorption studies of polyethers Part1. Adsorption onto hydrophobic surfaces. Colloid Surface A 136 (1-2): 21-33. [5] Schubert, M. A. and Muller-Goymann, C. C. (2005). Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsi-fier. Eur J Pharm Biopharm 61: 77-86.FIzIChKO-khEMISKI OSObININA Plga AMFIFIlNI NANOChESTIChKII TARGETIRAnjE NA TsVRSTI TUMORIM. Simonoska Tsrtsarevska1, N. Geshkovski1,M. Glavash Dodov1, S. Chalish2, S. Dimchevska1,K. Gorachinova11Farmatsevtski fakultet, Univerzitet ,,Sv. Kiril i Metodij",Vodnjanska 17, 1000 Skopje, Makedonija2Farmatsevtski fakultet, Khadzhetepe Univerzitet,06100 Ankara, TurtsijaPolimernite terapevtitsi pretstavuvaat novo shiroko pole za ra-zvoj na alternativni strategii vo terapijata na kantser. Predizvikpri formulatsijata na dozirani formi so nasocheno i kontroli-rano osloboduvanje e da se dizajniraat sistemi (nosachi) so sood-vetna kolichina na vgraden lek, koi kje mozhat efikasno dapominuvaat niz fizioloshki barieri na patot do mestoto na delu-vanje, koi kje imaat pogolema efikasnost vo terapijata, no i kje po-kazhat namaluvanje na intenzitetot i zachestenosta na poten-tsijalnite neskani efekti. Pasivniot targeting, koj se zasnova naspetsifichnite abnormalnosti asotsirani so tumornoto tkivo, pret-stavuva pristap vo formulatsijata na nanonosachot koj ovozmozhuvada se namali fagotsitozata i/ili da se prodolzhi vremeto natsirkulatsija vo sistemskiot krvotok. Pri toa, posebno vnimanie trebada se posveti na fizichko-khemiskite osobini na dizjanirnatitesistemi, t.e.